In a report released yesterday, Marie Thibault from BTIG maintained a Hold rating on Masimo (MASI). The company’s shares closed last Tuesday at $251.18, close to its 52-week high of $258.00.
According to TipRanks.com, Thibault is a 5-star analyst with an average return of 28.7% and a 53.1% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $255.00 average price target.
See today’s analyst top recommended stocks >>
Based on Masimo’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $301 million and net profit of $55.77 million. In comparison, last year the company earned revenue of $230 million and had a net profit of $44.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
